Log in

NASDAQ:CERCCerecor Stock Price, Forecast & News

$2.57
+0.01 (+0.39 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.52
Now: $2.57
$2.59
50-Day Range
$2.26
MA: $2.63
$3.23
52-Week Range
$1.52
Now: $2.57
$6.19
Volume219,900 shs
Average Volume561,814 shs
Market Capitalization$153.20 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86
Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device. The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-406 for the treatment of Parkinson's disease; CERC-425, an orally active small molecule; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and CERC-913, a protide nucleotide for the treatment of mitochondrial disorder. It also developing preclinical therapies CERC-801, CERC-802, and CERC-803 for the treatment of inherited metabolic disorders. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.26 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CERC
CUSIPN/A
Phone410-522-8707

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.75 million
Book Value$0.40 per share

Profitability

Net Income$-16,070,000.00

Miscellaneous

Employees64
Market Cap$153.20 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive CERC News and Ratings via Email

Sign-up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter.

Cerecor (NASDAQ:CERC) Frequently Asked Questions

How has Cerecor's stock been impacted by COVID-19 (Coronavirus)?

Cerecor's stock was trading at $2.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CERC stock has increased by 6.6% and is now trading at $2.57. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cerecor?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerecor in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cerecor.

When is Cerecor's next earnings date?

Cerecor is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cerecor.

How were Cerecor's earnings last quarter?

Cerecor Inc (NASDAQ:CERC) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.08. The firm had revenue of $2.75 million for the quarter, compared to analysts' expectations of $2.25 million. View Cerecor's earnings history.

What price target have analysts set for CERC?

4 brokers have issued 1 year price objectives for Cerecor's shares. Their forecasts range from $10.00 to $12.00. On average, they expect Cerecor's stock price to reach $10.50 in the next year. This suggests a possible upside of 308.6% from the stock's current price. View analysts' price targets for Cerecor.

Has Cerecor been receiving favorable news coverage?

Headlines about CERC stock have been trending somewhat negative on Saturday, InfoTrie reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cerecor earned a daily sentiment score of -1.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Cerecor.

Who are some of Cerecor's key competitors?

What other stocks do shareholders of Cerecor own?

Who are Cerecor's key executives?

Cerecor's management team includes the following people:
  • Ms. Mariam E. Morris, Consultant (Age 51)
  • Dr. Simon C. Pedder Ph.D., Exec. Chairman (Age 58)
  • Mr. Joseph M. Miller CPA, Chief Financial Officer (Age 45)
  • Dr. Solomon H. Snyder, Founder and Chairman of Scientific Advisory Board (Age 80)
  • Dr. Barbara S. Slusher, Founder and Member of Scientific Advisory Board (Age 54)

What is Cerecor's stock symbol?

Cerecor trades on the NASDAQ under the ticker symbol "CERC."

How do I buy shares of Cerecor?

Shares of CERC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cerecor's stock price today?

One share of CERC stock can currently be purchased for approximately $2.57.

How big of a company is Cerecor?

Cerecor has a market capitalization of $153.20 million and generates $6.75 million in revenue each year. The company earns $-16,070,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis. Cerecor employs 64 workers across the globe.

What is Cerecor's official website?

The official website for Cerecor is www.cerecor.com.

How can I contact Cerecor?

Cerecor's mailing address is 540 Gaither Road Suite 400, Rockville MD, 20850. The company can be reached via phone at 410-522-8707 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.